Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A Trial of FANG™ Vaccine for Participants With Ovarian Cancer [Phase 2]
Phase 2 trial update for the FANG Vaccine in ovarian cancer; the study is completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer [Phase 2]
Phase 2 trial update of olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube, and primary periton…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. [Phase 3]
Phase 3 trial evaluating olaparib beyond progression versus platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer [Phase 3]
A Phase 3 trial comparing weekly versus every 3-week chemotherapy regimens in patients with ovarian cancer; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer [Phase 2]
Phase 2 trial update evaluating pembrolizumab in combination with chemotherapy as frontline treatment for advanced ovarian, primary peritone…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study [Phase 2]
Phase 2 translational study evaluating olaparib in recurrent ovarian cancer with BRCA1/2 wild-type, focusing on platinum-sensitive cases.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer [Phase 3]
Phase 3 clinical trial update exploring bevacizumab beyond progression in platinum-sensitive recurrent ovarian cancer is reported, though st…
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]
This Phase 3 trial evaluated bevacizumab in addition to standard therapy for newly diagnosed Stage III/IV epithelial ovarian, fallopian tube…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors [Phase 1]
Phase 1 trial update on an arginase-1 peptide vaccine in patients with metastatic solid tumors, including non-small cell lung cancer and uro…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study [Phase 2]
Phase 2 trial update for enzalutamide in metastatic or advanced non-resectable granulosa cell ovarian tumors (GREKO III) completed.
-
CLINICAL_TRIALS trial_result · 2023-02-17Clinical Trial Update: A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]
Phase 3 trial comparing atezolizumab plus paclitaxel, carboplatin, and bevacizumab versus control in newly diagnosed ovarian, fallopian tube…
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients [Phase 2]
A Phase 2 clinical trial update on heated intraperitoneal chemotherapy for ovarian cancer, with unclear status.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors [Phase 2]
Phase 2 study evaluating Navicixizumab as monotherapy or in combination in patients with select advanced solid tumors, including colorectal …
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating pembrolizumab after weekly paclitaxel in platinum-resistant ovarian, fallopian tube, or peritoneal cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin [Phase 2]
Phase 2 trial evaluating olaparib with liposomal doxorubicin in resistant advanced ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating irinotecan liposome with bevacizumab for platinum-resistant or recurrent ovarian, fallopian tube, or prima…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) [Phase 3]
Phase 3 trial of VB-111 plus paclitaxel versus paclitaxel alone in recurrent platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of Enapotamab Vedotin in solid tumors, including ovarian and cervical cancer; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer [Phase 1, Phase 2]
Clinical trial update for GL-ONC1 oncolytic immunotherapy in recurrent or refractory ovarian cancer (Phase 1/Phase 2) completed.
-
CLINICAL_TRIALS trial_result · 2023-01-03Clinical Trial Update: Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy [Phase 2]
Phase 2 trial evaluating pamiparib with tamoxifen for epithelial ovarian cancer patients with biochemical recurrence during first-line PARP …
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse [Phase 3]
Phase 3 trial of farletuzumab with carboplatin and taxane in platinum-sensitive ovarian cancer at first relapse was terminated; results post…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer [Phase 2]
Phase 2 trial update on neoadjuvant chemotherapy for epithelial ovarian cancer with related fallopian tube and peritoneal carcinomas; curren…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer [Phase 2]
This Phase 2 trial evaluated the activity of combining nivolumab and ipilimumab in patients with recurrent or persistent clear cell ovarian …
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating ONCOS-102 in combination with durvalumab in advanced peritoneal malignancies (colorectal, ovarian, and appendicea…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer [Phase 2]
Phase 2 trial comparing Folate Receptor Alpha Peptide Vaccine with GM-CSF versus GM-CSF alone in platinum-sensitive ovarian cancer was termi…